GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gain Therapeutics Inc (NAS:GANX) » Definitions » Total Current Liabilities

Gain Therapeutics (Gain Therapeutics) Total Current Liabilities : $5.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gain Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Gain Therapeutics's total current liabilities for the quarter that ended in Mar. 2024 was $5.00

Gain Therapeutics Total Current Liabilities Historical Data

The historical data trend for Gain Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gain Therapeutics Total Current Liabilities Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 0.88 2.12 2.55 4.13 4.95

Gain Therapeutics Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.16 5.59 5.76 4.95 5.00

Gain Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Gain Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.43+0.348
+Other Current Liabilities+Current Deferred Liabilities
=0.0010000000000003+1.171
=4.95

Gain Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.699+0.315
+Other Current Liabilities+Current Deferred Liabilities
=0.00099999999999945+0.989
=5.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Gain Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Gain Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gain Therapeutics (Gain Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gain Therapeutics Inc (NAS:GANX) » Definitions » Total Current Liabilities
Comparable Companies
SLGL HOOK PASG COEP INKT RZLT PRTG BOLT BYSI NERV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Website
https://www.gaintherapeutics.com
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements.
Executives
Matthias Alder officer: Chief Operating Officer C/O MICROMET, INC., 6707 DEMOCRACY BLVD., STE. 505, BETHESDA MD 28017
Charles Evan Ballantyne officer: Chief Financial Officer 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Gianluca Fuggetta officer: Principal Accounting Officer C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA MD 20814
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Salvatore Calabrese officer: Chief Financial Officer C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Goldstein Dov A Md director
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Claude Nicaise director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Manolo Bellotto officer: President and General Manager C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814

Gain Therapeutics (Gain Therapeutics) Headlines

From GuruFocus

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews • 07-02-2022

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

By GuruFocusNews GuruFocusNews • 06-30-2022

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

By sperokesalga sperokesalga • 04-12-2023

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

By GuruFocusNews GuruFocusNews • 07-10-2022

Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress

By GuruFocusNews GuruFocusNews • 06-25-2022

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

By Marketwired • 08-28-2023

Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences

By Stock market mentor Stock market mentor • 02-02-2023

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

By PurpleRose PurpleRose • 07-12-2022

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

By GuruFocusNews GuruFocusNews • 06-25-2022

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

By sperokesalga sperokesalga • 03-29-2023